Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B - Full Text View

Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B (EVD)

This study has been withdrawn prior to recruitment.

( Sponsor withdraw )

First Received: July 2, 2008 Last Updated: April 16, 2009 History of Changes

Sponsors and Collaborators:	University of Ulm Novartis
Information provided by:	University of Ulm
ClinicalTrials.gov Identifier:	NCT00710216

Purpose

This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.

Condition	Intervention	Phase
Hepatitis B, Chronic	Drug: Lamivudine Drug: Telbivudine	Phase IV

MedlinePlus related topics: Hepatitis Hepatitis B

Drug Information available for: Lamivudine Telbivudine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title:	Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study)

Further study details as provided by University of Ulm:

Primary Outcome Measures:

Decrease in viral load after 2 weeks of therapy measured in serum HBV-DNA concentration (Copies/ml or IU/ml). [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Course of the viral load (serum HBV-DNA) during the first 12 weeks of therapy [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Influence of HBeAg status to the decrease in viral load [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Influence of HBV genotype to the decrease in viral load [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Change in ALT and AST levels from Baseline to Week 12 [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Development of viral resistance and treatment failure during the study and subsequent course of observation [ Time Frame: 6 month ] [ Designated as safety issue: No ]
Safety assessed by adverse events and laboratory values [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]

Estimated Enrollment:

Arms	Assigned Interventions
A: Active Comparator	Drug: Lamivudine 100 mg/day
B: Experimental	Drug: Telbivudine 600 mg/day

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Documented compensated HBeAg-positive or negative chronic hepatitis B
Increased viral load with a concentration of serum HBV-DNA of at least 10^4 copies/ml
Proof of inflammatory activity in the liver: ALT ≥ 2 x ULN or histological evidence of inflammatory activity ≥ level I or fibrosis of ≥ I degrees (according to the Desmet classification)
Negative urine pregnancy test with fertile women
Willingness to use a recognized method of contraception
Able to comply with study regimen and provide written informed consent

Exclusion Criteria:

Current or previous antiviral treatment of chronic hepatitis B with Nucleus(t)id analoga
Known hypersensitivity to lamivudine or telbivudine or any of the other components of the preparations
Pregnant or breastfeeding women or women
Simultaneous participation in other clinical trials or in the past three months
Co-infected with HCV, HDV, HIV
Other non HBV-related chronic liver disease: Autoimmune hepatitis, primary biliary cirrhosis, Hemochromatosis, alpha-1 antitrypsin deficiency, alcoholic hepatitis
Evidence of hepatocellular carcinoma (alpha-fetoprotein levels> 100 ng/ml)
Active drug use, including an excessive alcohol consumption during the last 6 months before participating in the clinical trial
Use of systemic treatment with anti-neoplastic or immunomodulatory medication within the last 6 months before participating in the clinical trial and during the duration of the clinical examination
Lack of willingness or inability to consent in writing
Concurrent condition likely to preclude compliance with schedule of evaluations

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00710216

Locations

Germany
University Hospital Ulm
Ulm, Germany, 89081

Sponsors and Collaborators

University of Ulm

Novartis

Investigators

Principal Investigator:

Nektarios Dikopoulos, MD

University Hospital Ulm

More Information

Additional Information:

University Hospital Ulm This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Universitätsklinikum Ulm ( PD Dr. med. Nektarios Dikopoulos )
Study ID Numbers:	EVD-001
Study First Received:	July 2, 2008
Last Updated:	April 16, 2009
ClinicalTrials.gov Identifier:	NCT00710216 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Ulm:

Viral kinetics
Viral dynamics
Telbivudine
Lamivudine

Study placed in the following topic categories:

Liver Diseases
Anti-HIV Agents
Hepatitis, Chronic
Hepatitis, Viral, Human
Lamivudine
Antiviral Agents
Reverse Transcriptase Inhibitors

Hepatitis
Virus Diseases
Digestive System Diseases
Anti-Retroviral Agents
Hepatitis B, Chronic
Hepatitis B
DNA Virus Infections

Additional relevant MeSH terms:

Anti-Infective Agents
Liver Diseases
Anti-HIV Agents
Molecular Mechanisms of Pharmacological Action
Hepatitis, Chronic
Hepatitis, Viral, Human
Lamivudine
Enzyme Inhibitors
Antiviral Agents
Hepadnaviridae Infections
Pharmacologic Actions

Reverse Transcriptase Inhibitors
Hepatitis
Virus Diseases
Digestive System Diseases
Anti-Retroviral Agents
Therapeutic Uses
Hepatitis B, Chronic
Hepatitis B
DNA Virus Infections
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on May 07, 2009